Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE)Discover the Best Stocks and Maximize Your Portfolio: ...

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...

Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics ...

Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...

Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...